Neuracle Science Co., Ltd.

Neuracle Genetics Inc.

Juwon Shim

Dong Sik Kim

Jae-Keun Lee

Bongcheol Kim

Soon-gu Kwon

Jong-Mook Kim

Jae Young Seong

Eun Bee Cho

Shin-Hyuk Kang

Tae Woo Kim

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.

Use of anti-FAM19A5 antibodies for treating atherosclerosis

The present disclosure provides adeno-associated vims (AAV) vectors and uses thereof. In certain embodiments, the AAV vectors comprise a nucleic acid that encodes an antagonist against a family with sequence similarity 19, member A5 (FAM19A5) protein, e.g., anti-FAM19A5 antibody, e.g., anti-FAM19A5 scFv.

Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.

Use of anti-FAM19A5 antibodies for treating cancers

Growing community of inventors

Seoul, South Korea

Juwon Shim